The moment of the 1-year assessment (before/after COVID-19) was not significantly associated with cognitive decline [aOR (95% CI): 0.95 (1.41-32.87)] and the interaction with ADT-based treatments was not statistically significant ( P = 0.233), but the association between the COVID-19 pandemic and incident cognitive impairment was nearly statistically significant [aOR (95% CI): 2.65 (0.95-7.23)] and its interaction with ADT-based treatments was significant ( P = 0.044).
← all excerpts
Androgen-deprivation therapy and cognitive decline in the NEON-PC prospective study during the COVID-19 pandemic.
1
—
—